Companion Diagnostics & Precision Health

- A Deeper Dive directed toward the Details of the Backstory -
CDx-Stratified Health

At the confluence of pharmaco-genomic-driven drug-discovery, diagnostics and therapeutics is stratified or precision medicine.

Dx, PGx & Rx Convergence

The triple helix, illustrated above, represents converging molecular diagnostics, pharmacogenomics and targeted therapeutics.

Precision Healthcare

Pharmacogenomic markers, companion diagnostic testing and bioinformatic tools are enabling CDx-stratified precision health.

CDx Precision Health is helping level the financial-playing field among the various stratified healthcare stakeholders. Get in touch with us today to see how we can help bolster your CDx company’s business development deal-negotiation position versus your opponents.

Please include attribution to with this graphic.

To drive the point home we’ve highlighted 4 biomarkers:

1. Hot – PD-L1: On the tips of the tounges of many of us in the industry, PD-L1 has been used extensively in a short period of time. PD-L1 represents the clearest example of a Hot biomarker in our quadrant and a biomarker that seems to have quickly tipped into significant commericial value.

2. Common – HER2 and A1C: Representing the well known stalwarts of the biomarker landscape HER2 and A1C falls in our Common quadrant. Not surprisingly they’ve been around for a long time and used extensively throughout the market. A1C is interesting because it’s boarderline when considering a strict definition of a biomarker. However, it’s ubiquity and acceptance in patient management and clinical trials compels coverage in BiomarkerBase.

3. Underperforming – p16: Our Under-performing biomarkers are represented by p16. p16 has been around for almost 30 years, but has seen very little adoption by companies.

What are those strings of biomarkers in the bottom right?

You may have noticed the lines of biomarkers in the lower right quadrant. More on this after we’ve done some more analysis, but we believe this represents two trends:

1. The commercial value of companies developing novel biomarkers
2. The need for viable companion diagnostics